Portfolio Decisions in Early Development

  title={Portfolio Decisions in Early Development},
  author={Michael Dr Herschel},
  journal={Pharmaceutical Medicine},
  • M. Herschel
  • Published 1 April 2012
  • Psychology, Medicine
  • Pharmaceutical Medicine
Portfolio decisions in early development happen under much uncertainty. Particularly when a novel target or treatment method is being explored, early negative clinical results may lead to the discontinuation of compound development, or even of an entire branch of discovery research. Although we can find examples where ‘failed’ concepts have been picked up later and shown to work, there is no way to estimate how large the percentage of false negative discontinuations may be as this type of… Expand
2 Citations
Improving target assessment in biomedical research: the GOT-IT recommendations
Academic research plays a key role in identifying new drug targets, including understanding target biology and links between targets and disease states. To lead to new drugs, however, research mustExpand
Mitigating risk in academic preclinical drug discovery
Strategies to mitigate risks in several key aspects of preclinical drug discovery at academic drug discovery centres are discussed, including organization, target selection, assay design, medicinal chemistry and preclinical pharmacology. Expand


Valuation of biomarkers
The potential value of non-surrogate biomarkers intended to reduce failure of subsequent trials are focused on, which is beyond the scope of this article, but much of the current literature is devoted to those designed to predict either efficacy or toxicity of a drug treatment. Expand
When are "positive" clinical trials in oncology truly positive?
The approval of a new drug for cancer treatment by the regulatory authorities, such as the United States Food and Drug Administration or European Medicines Agency, is usually based on the positiveExpand
Assessing the translatability of drug projects: what needs to be scored to predict success?
  • M. Wehling
  • Computer Science, Medicine
  • Nature Reviews Drug Discovery
  • 2009
How a scoring system to systematically assess key determinants of translational success, such as biomarkers and animal and human data, could help identify deficiencies and potential improvements, and increase the reliability of portfolio risk estimates is discussed. Expand
Stopping clinical trials by design
Why a 'stopping rule' might be intended to prevent participants from continuing to receive a drug that already seems to be unsafe, and what can be done to promote their successful and beneficial use in the future. Expand
Portfolio analysis and R&D decision making
This article proposes that current typical practices are suboptimal, that decision making can be improved using standard portfolio analysis, and that this more complete approach can be integrated into existing forecasting and planning processes with minimal disruption. Expand
Trial watch: Phase II failures: 2008–2010
Well-conducted Phase II clinical trials provide the data required to determine whether there is a case to be made, both scientifically and commercially, for progressing a drug candidate into Phase III trials, but results are lower than at any other phase of development. Expand
How to improve R&D productivity: the pharmaceutical industry's grand challenge
A detailed analysis based on comprehensive, recent, industry-wide data is presented to identify the relative contributions of each of the steps in the drug discovery and development process to overall R&D productivity and propose specific strategies that could have the most substantial impact in improving R &D productivity. Expand
Developing drug prototypes: pharmacology replaces safety and tolerability?
  • A. Cohen
  • Computer Science, Medicine
  • Nature Reviews Drug Discovery
  • 2010
There is an increasing number of new prototypical compounds resulting from the increased biological knowledge with a high level of uncertainty, and for these prototypical drugs development has to proceed in a much more adaptive manner, using tailor-made objectives, the development of special methodology and a cyclical rather than a linear type of project management. Expand
The influence of drug-like concepts on decision-making in medicinal chemistry
Analysis of recent trends reveals that the physical properties of molecules that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compounds in clinical development. Expand
Key factors in the rising cost of new drug discovery and development
Studies on the cost of developing new drugs are reviewed and how this cost has, and could be, affected by the changing environment for pharmaceutical research and development are considered. Expand